Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

Eisai and Biogen’s Alzheimer’s drug Leqembi has received a thumbs down from the European Medicines Agency’s expert committee, which raised concerns about safety and limited efficacy.

The news is a major setback for the two companies, as the EU is expected to be the second biggest market for the drug after the US. Eisai, which is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

16 Sep 2024

• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

23 Aug 2024

• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.